Mydecine proves its clinical and commercial psilocybin mushroom supply change was a success, as it completes its first international shipment from its cultivation facility in Jamaica to its cGMP facility in Canada.

It is a sunny December day in Jamaica and Mydecine Innovations Group is in a private mycology-focused research and cultivation facility starting its first psilocybin mushroom harvest. 40 kilograms of “Magic” Psilocybin Mushrooms will be dried and shipped to Mydecine’s Canadian Current Good Manufacturing Practice facility, which has a Health Canada Schedule 1 Dealer’s License attached to it, allowing for legal import/export, research and development, cultivation, and commercial sale of active psychedelic medicinal compounds. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Damon Michaels, Mydecine's Co-Founder and Chief Operating Officer released a statement last week, “We have delivered on our promise. Our legal international supply chain of psilocybin mushrooms is now officially complete. This makes another historical milestone in the overall progress to bring psychedelic medicine to the world.”